Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Pleased to share our new paper out today in the British Journal of Haematology.
This is a post-hoc analysis of the BEYOND trial specifically looking at the proportion of NTDT patients that reached and sustained a hemoglobin level of >10 g/dL while on ß, reflecting clinically meaningful impact considering this would now place them in the ‘safe zone’.”
Read the full article in BJHaem.
Article: Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial
Authors: Khaled Musallam X, Ali T. Taher, John B. Porter, Antonis Kattamis, Mrudula B. Glassberg, Luciana Moro Bueno, Patricia Martin-Regueira, Marta Reverte, Loyse Felber Medlin, Matthew Dyer, Kefeng Wang, Maria Domenica Cappellini
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 4, 2026, 03:51Riana Gjeta: Sharing Research on Blood Donor Safety in the Balkans
-
Nov 4, 2026, 03:48Umberto Pensato: World Stroke Congress – Science, Collaboration, and Recognition
-
Nov 4, 2026, 03:41Alejandro González Veliz: Understanding and Managing Stent Underexpansion
-
Nov 4, 2026, 03:26Violeta Jardin: The Evolution of Viscoelastic Testing
-
Nov 4, 2026, 03:12Daniele Sannipoli: Beyond Thrombosis Prevention in Polycythaemia Vera
-
Nov 4, 2026, 02:26Iris Paola Garcia Herrera: Antiphospholipid Antibodies in Children Beyond Thrombosis
-
Nov 4, 2026, 00:31Maria Cherska: Beyond LDL – Remnant Cholesterol and Stroke Prognosis
-
Nov 3, 2026, 22:00Ravi C Dara: What’s New in ASFA’s 10th Edition – Practical Updates for the Apheresis Clinician
-
Nov 3, 2026, 21:46Cedric Hermans: Treatment Differentiators for Shared Decision-Making in Haemophilia in 2026